Navigation Links
Novavax Reports First Quarter 2009 Financial Results
Date:5/8/2009

ROCKVILLE, Md., May 8 /PRNewswire-FirstCall/ - Novavax Inc. (Nasdaq: NVAX) today announced financial results for the first quarter of 2009. Novavax reported a net loss of $8.3 million, or $0.12 per share, for the first quarter of 2009 compared to a net loss of $7.8 million, or $0.13 per share, for the first quarter of 2008. The Company spent a total of $7.4 million in the first quarter of 2009 and ended the quarter with $25.6 million in cash and short-term investments. During the quarter, the Company made significant progress in developing its vaccine pipeline, improved its balance sheet by raising capital and retiring a majority of its convertible debt, and completed a transaction with Cadila Pharmaceutical Limited to create a Joint Venture Company in India.

Specifically accomplishments since the 2008 year end financial results include the following:

  • Commenced development of a VLP vaccine candidate against the novel influenza A (H1N1) virus that has recently emerged in the United States and Mexico.
  • Publication of results in the Journal of Virology from preclinical studies conducted under a collaborative research and development agreement (CRADA) between the Centers for Disease Control and Prevention (CDC) and Novavax showing that an investigational H1N1 VLP vaccine based on the 1918 Spanish influenza strain protected against both the Spanish flu and a highly pathogenic H5N1 avian influenza strain.
  • Announced the initiation of enrollment in the second Phase II study of its trivalent seasonal influenza VLP vaccine candidate. This clinical trial is designed to evaluate the safety and immunogenicity of a broader range of vaccine doses and to provide data to help select doses for future studies in older adults and a Phase III efficacy study. The Company plans to report top-line immunogenicity and safety results from this study by the fourth quarte
    '/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
2. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
3. Novavax Announces Early Retirement of $17 Million of Convertible Debt
4. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
5. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
6. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
7. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
8. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
9. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
10. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
11. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... Massachusetts, USA (PRWEB) November 26, 2014 ... more accuracy, additive systems to enable 3D manufacture at ... analyzing road conditions are among finalists in nine categories ... . The awards are sponsored by SPIE, the ... Photonics Media . , Winners will be announced by ...
(Date:11/26/2014)... In keeping with the holiday spirit, DNA ... Thanksgiving savings. The company is offering up a variety ... this holiday weekend as well as a photo contest ... Monday are right around the corner, and DNA Spectrum ... and those looking to explore their ancestry, health, and ...
(Date:11/26/2014)... 2014 The ETC (Emerging Technology ... innovation centers, announced today that applications for AccelerateBaltimore™ ... 1st. “Do you have a big idea?,” asked ... to know about it. AccelerateBaltimore helps you and ... in just 13 weeks.” Interested game changers ...
(Date:11/26/2014)... 2014 Continuing its award-winning streak, Nerium ... prestigious MarCom Awards for outstanding creative achievement by its ... MarCom Award, the organization’s top honor, in the Branding ... held in April of this year. The event showcased ... Additionally, Nerium was awarded a Gold MarCom Award in ...
Breaking Biology Technology:Finalists Named for 2015 Prism Awards for Photonics Innovation 2Finalists Named for 2015 Prism Awards for Photonics Innovation 3Finalists Named for 2015 Prism Awards for Photonics Innovation 4Finalists Named for 2015 Prism Awards for Photonics Innovation 5DNA Spectrum Offers Last Minute Thanksgiving Coupons 2DNA Spectrum Offers Last Minute Thanksgiving Coupons 3AccelerateBaltimore Applications to Close in 6 Days 2AccelerateBaltimore Applications to Close in 6 Days 3Nerium International™ Wins One Platinum, Two Gold MarCom Awards 2
... FRANCISCO, March 11 VIA Pharmaceuticals,(Nasdaq: VIAP ... of,compounds for the treatment of cardiovascular disease, announced ... James G. Stewart, senior,vice president and chief financial ... Cowen and Company 28th Annual Health Care Conference ...
... Sunesis,Pharmaceuticals, Inc. (Nasdaq: SNSS ), a clinical-stage ... of,novel small-molecule therapeutics, today reported financial results for ... Total revenue for the fourth quarter of ... $8.8 million. Total revenue for the year ended ...
... N.J., March 11 Pharmacopeia,(Nasdaq: PCOP ), an ... therapeutics, today announced that Dr. Leslie J. Browne,President and ... Cowen and Company 28th Annual Health Care Conference.,The conference ... The Boston Marriott,Copley Place, Boston, Massachusetts., Dr. Browne,s ...
Cached Biology Technology:Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 2Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 3Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 4Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 5Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 6Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 7Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 8Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 9Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 10Pharmacopeia to Present at the Cowen and Company 28th Annual Health Care Conference 2Pharmacopeia to Present at the Cowen and Company 28th Annual Health Care Conference 3
(Date:11/3/2014)... from Australia report that low birth weight and preterm ... hip replacements in adulthood. Findings published in the American ... Research , indicate that low birth weight and pre-term ... due to OA as adults. , According to ... 25 are diagnosed with clinical OA. Symptoms of OA ...
(Date:11/2/2014)... (2 November 2014)—In support of a bold quest to ... Melinda Gates Foundation today announced an award of US$156 ... Initiative (MVI) in building new vaccines that will interrupt ... the "accelerating to zero" agenda. Such vaccines would ensure ... be called an "immunological bed net." , This ...
(Date:11/2/2014)... a bar and bump into a biologist . . . ... late-night nerd sketch, researchers have taken this premise and applied ... finding meaning in the rising oceans of genomic data. , ... that genome-wide studies are publishing at a dizzying rate. The ... signal from the noise (and there is no shortage of ...
Breaking Biology News(10 mins):Preterm, low birth-weight babies may need new hips in adulthood 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 3New malaria vaccines to prevent infection and block transmission get a shot in the arm 4Mutant models 2Mutant models 3Mutant models 4
... patients miserable and debilitated with chronic itching or pain ... possible paralysis or damage to the brain and other ... effective treatment even though the responsible gene was identified ... done to treat a disease that affects more people ...
... have identified a specific protein molecule that is used ... leading the way for development of future vaccines to ... issue of Science Express, the study provides insight into ... problem of great scientific and clinical importance. , Most ...
... field trials in China report higher crop yields, reduced ... a study by researchers in China and at Rutgers ... of the study will appear in the April 29 ... two of the four GM varieties that are now ...
Cached Biology News:Potential treatments for neurofibromatosis 2Potential treatments for neurofibromatosis 3Yale researchers identify molecule for detecting parasitic infection in humans 2Genetically modified rice in China benefits farmers' health, study finds 2Genetically modified rice in China benefits farmers' health, study finds 3Genetically modified rice in China benefits farmers' health, study finds 4